New diabetes injection aims for better blood sugar control with less weight gain
NCT ID NCT06871761
Summary
This study tested whether a new injectable medication called HR17031 works better and is safer than a standard long-acting insulin (glargine) for adults with type 2 diabetes. It involved 393 people whose blood sugar was not well controlled on their current insulin and pill regimen. Researchers compared how well each treatment lowered average blood sugar (HbA1c) and affected body weight over 26 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Zhu Xianyi Memorial Hospital, Tianjin Medical University
Tianjin, Tianjin Municipality, 300400, China
Conditions
Explore the condition pages connected to this study.